With hep C franchises languishing, Merck’s MK-3682 goes from blockbuster to bomb
A little less than three years after acquiring the hepatitis C drug MK-3682 (uprifosbuvir) in its $3.85 billion buyout of Idenix, Merck’s prospects in the field have cooled dramatically, and its once great hopes for the drug have been reduced to nearly nothing.
After the market closed on Thursday, Merck says it is taking a pre-tax $2.9 billion “intangible asset impairment charge” for the drug and reducing it on the books to a marginal $240 million — and even that may not last long.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.